Similar articles

• Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.

  Swindle JP, Potash J, Kulakodlu M, Kuznik A, Buikema A. Swindle JP, et al. Am J Geriatr Pharmacother. 2011 Dec;9(6):471-82. doi: 10.1016/j.amjopharm.2011.09.004. Epub 2011 Oct 21. Am J Geriatr Pharmacother. 2011. PMID: 22019005
• Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.

  Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Becker ML, et al. Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):75-81. doi: 10.1002/pds.1866. Pharmacoepidemiol Drug Saf. 2010. PMID: 19802823
• Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.

  Bożentowicz-Wikarek M, Kocełak P, Smertka M, Olszanecka-Glinianowicz M, Chudek J. Bożentowicz-Wikarek M, et al. Pharmacol Rep. 2012;64(2):377-85. doi: 10.1016/s1734-1140(12)70778-8. Pharmacol Rep. 2012. PMID: 22661189
• Safety of high-dose atorvastatin therapy.

  Waters DD. Waters DD. Am J Cardiol. 2005 Sep 5;96(5A):69F-75F. doi: 10.1016/j.amjcard.2005.06.028. Am J Cardiol. 2005. PMID: 16126026 Review.
• Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.

  Zhou Z, Rahme E, Pilote L. Zhou Z, et al. Am Heart J. 2006 Feb;151(2):273-81. doi: 10.1016/j.ahj.2005.04.003. Am Heart J. 2006. PMID: 16442888 Review.